Tuesday, March 14, 2023

Eli Lilly launches Copellor® (Ixekizumab) in India,

Eli Lilly launches Copellor® (Ixekizumab) in India, for the treatment of adults with moderate-to-severe plaque psoriasis as well as for adult patients with active psoriatic arthritis

Psoriasis is a chronic, immune-mediated, inflammatory disease, affecting 125 million individuals worldwide.1
 In India, the prevalence of psoriasis varies from .44 to 2.8% and the incidence of Psoriatic arthritis is estimated to range from 7% to 42% among all psoriasis patients.2,3

New Delhi, March 14th: Eli Lilly, following approval from The Drug Controller General of India (DCGI) announced the launch of Copellor®(Ixekizumab) in India for the treatment of adults with moderate-to-severe plaque psoriasis as well as for adult patients with active psoriatic arthritis. A humanized IgG4 monoclonal antibody, Copellor®(Ixekizumab) is designed to specifically target IL-17A, a protein that plays a role in triggering and maintaining inflammation in psoriasis.4

Vineet Gupta, Managing Director, Eli Lilly and Company - India & India Subcontinent said, “Our foray into the dermatology segment strengthens Lilly’s promise of bringing innovative medicines to India. Global Studies show that the impact psoriasis has on a patient’s quality of life is comparable to that of ‘serious’ diseases such as cancer and heart failure.5The availability of a new treatment like Copellor®(Ixekizumab) will now empower healthcare providers with another option to successfully treat adults with moderate-to-severe plaque psoriasis and adult patients with active psoriatic arthritis, a huge unmet need in the country.”
Copellor®(Ixekizumab) is a prescription medicine to be used only on the advice of a dermatologist or rheumatologist and under medical supervision. 
It is available in one strength of 80 mg/ml in a single dose prefilled autoinjector.6

About Psoriasis and Psoriatic Arthritis
Psoriasis is a chronic auto-immune disorder of the skin in which prolonged inflammation leads to dry, thick, raised, red patches on the skin that continuously shed silvery scales.4 These patches cause great discomfort to the patient because they are accompanied by unstoppable itching. It can affect their daily activities such as dressing, walking, cooking and typing. Several studies show that patients with severe psoriasis are prone to depression and may even develop a suicidal tendency.7
Psoriasis can also lead to a painful condition of the joints known as ‘psoriatic arthritis.’ Research shows that in psoriasis, inflammation is present throughout the body and this increases the risk of heart disease, diabetes, kidney diseases and inflammatory bowel diseases8 along with psoriasis. There is no single cause identified for this condition, but there are a number of contributing factors: genetic risk, environmental triggers such as obesity, stress, some drugs, and injury.9 

About Copellor6
Copellor®(Ixekizumab) is a humanized IgG4 monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Ixekizumab inhibits the release of pro-inflammatory cytokines and chemokines.

About Eli Lilly and Company 
Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To lLilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram and LinkedIn. 

About Lilly India
Eli Lilly and Company (India) Pvt. Ltd. (Lilly India), headquartered in Gurgaon, is a wholly-owned subsidiary of Eli Lilly and Company, a global biopharmaceutical company headquartered in Indianapolis, USA. Since its inception nearly 30 years ago, Lilly India has been committed to offering advanced treatment options to treat chronic diseases such as diabetes, breast cancer, lung cancer, gastric cancer, rheumatoid arthritis and osteoporosis. To learn more about Lilly India, please visit us at https://www.lillyindia.co.in ; LinkedIn

No comments:

Post a Comment